Liao Xiuhua, Li Zhou, Dong Xiyuan, Zhang Hanwang
Reproductive Medicine Centre, Women and Children's Hospital of Fujian Province Fuzhou 350000, Fujian, China ; Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430030, Hubei, China.
Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430030, Hubei, China.
Int J Clin Exp Pathol. 2014 Sep 15;7(10):6992-7. eCollection 2014.
Endometrial preparation with exogenous estrogen is a common practice in frozen-thawed embryo transfer (FET) cycles. The objective of this study was to compare the clinical outcomes of two endometrial preparation groups, oral estradiol valerate tablets (OEV) group versus vaginal estradiol (VE) tablets group, in inadequate endometrium patients. This retrospective, single-center, cohort study of patients undergoing FET treatment between Jan. 2012 and Jun. 2013, at an academic IVF center, included 247 patients (cycles) with endometrial thickness < 8 mm on day 13 of the hormone replacement cycle: OEV group included 69 patients (cycles) who received continuous OEV from day 1 onwards up to the day of progesterone supplement, while VE group included 178 patients (cycles) who taken OEV from day 1 to day 12, and used VE tablets from day 13 till the day of progesterone supplement. Patients in VE group required more days and higher dosage of estradiol, but had thinner endometrium on the day of transfer. However, the increase of endometrial thickness was more, when compared to OEV-treated patients. The implantation rate and pregnancy rate were, though not significantly, higher in VE group.
Longer time of administration and higher dosage of estradiol usage did not have adverse effects on the clinical pregnancy rate. VE tablets may promote endometrial development and pregnancy success in FET cycles could not verify. Further study is needed to confirm the vaginal estradiol action on frozen-thawed embryo transfer cycles.
在冻融胚胎移植(FET)周期中,使用外源性雌激素进行子宫内膜准备是一种常见做法。本研究的目的是比较口服戊酸雌二醇片(OEV)组和阴道用雌二醇(VE)片组这两种子宫内膜准备方式在子宫内膜较薄患者中的临床结局。这项回顾性、单中心队列研究,对2012年1月至2013年6月在一家学术性体外受精中心接受FET治疗的患者进行,纳入了247例(周期)在激素替代周期第13天子宫内膜厚度<8mm的患者:OEV组包括69例(周期)从第1天开始持续服用OEV直至补充孕酮当天的患者,而VE组包括178例(周期)从第1天至第12天服用OEV,并从第13天开始使用VE片直至补充孕酮当天的患者。VE组患者所需的雌激素使用天数更多、剂量更高,但在移植当天子宫内膜更薄。然而,与接受OEV治疗的患者相比,其子宫内膜厚度增加更多。VE组的着床率和妊娠率虽无显著差异,但略高。
更长的给药时间和更高剂量的雌激素使用对临床妊娠率没有不良影响。VE片可能促进FET周期中的子宫内膜发育和妊娠成功,但无法证实。需要进一步研究来证实阴道用雌二醇在冻融胚胎移植周期中的作用。